

**Effects of erythropoiesis-stimulating agents on overall survival of International Prognostic Scoring System Low/Intermediate-1 risk, transfusion-independent myelodysplastic syndrome patients: a cohort study**

Emanuela Messa,<sup>1,2</sup> Daniela Gioia,<sup>2</sup> Elisa Masiera,<sup>2</sup> Anna Castiglione,<sup>3</sup> Manuela Ceccarelli,<sup>3</sup> Flavia Salvi,<sup>4,2</sup> Paolo Danise,<sup>5,2</sup> Alessandro Sanna,<sup>6,2</sup> Bernardino Allione,<sup>7,2</sup> Enrico Balleari,<sup>8,2</sup> Antonella Poloni,<sup>9,2</sup> Giovanni Cametti,<sup>10,2</sup> Dario Ferrero,<sup>11,2</sup> Rodolfo Tassara,<sup>12,2</sup> Carlo Finelli,<sup>13,2</sup> Margherita Bonferroni,<sup>14,2</sup> Pellegrino Musto,<sup>15,2</sup> Giuseppe Saglio,<sup>16,2</sup> Alessandro Levis<sup>2</sup> and Valeria Santini<sup>6,2</sup>

<sup>1</sup>Division of Hematology, ASLTO 4, Ivrea (Turin); <sup>2</sup>Fondazione Italiana Sindromi Mielodisplastiche Onlus, Alessandria; <sup>3</sup>Unit of Clinical Epidemiology, "Città della Salute e della Scienza di Torino" Hospital, Turin; <sup>4</sup>Division of Hematology, "SS. Antonio e Biagio" Hospital, Alessandria; <sup>5</sup>Division of Onco-Hematology Nocera-Pagani, ASL Salerno; <sup>6</sup>Division of Hematology, Azienda Ospedaliera Universitaria Careggi, University of Florence; <sup>7</sup>Division of Hematology, Azienda Ospedaliero-Universitaria "Città della Salute e della Scienza di Torino", Turin; <sup>8</sup>Internal Medicine Department, IRCCS San Martino, Genoa, Italy; <sup>9</sup>Division of Hematology, "Ospedali Riuniti", Ancona; <sup>10</sup>Division of Internal Medicine ASLTO5 Chieri (Turin); <sup>11</sup>Division of Hematology, Azienda Ospedaliero-Universitaria "Città della Salute e della Scienza di Torino", University of Turin; <sup>12</sup>Division of Medicine and Hematology, ASL2 Savonese, Savona; <sup>13</sup>Institute of Hematology "L. e A. Seràgnoli", "Sant'Orsola-Malpighi" University Hospital, Bologna; <sup>14</sup>Division of Hematology, "Santa Croce e Carle" Hospital, Cuneo, Italy; <sup>15</sup>IRCCS-CROB Regional Cancer Center of Basilicata, Rionero in Vulture, Potenza and <sup>16</sup>Division of Hematology, "Mauriziano" Hospital, Turin, Italy

Correspondence: santini@unifi.it  
doi:10.3324/haematol.2017.183590

Supplemental Figure 1. Analyses of baseline factors associated with HI-E in ESA-treated patients

